Synoptik-Fonden Report issue

Foundation

Organization Overview

First Clinical Trial
2018
NCT03651011
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Synoptik-Fonden

Active Ingredients

Drugs in Other Trials (1)

aflibercept (zaltrap) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1